On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells.
“The assay from Rarity shows similar or better CV than current available ddPCR assays, and a much more cost efficient alternative. Based on the sensitivity and robustness of Rarity’s technique, we hope to use this technique for detecting CAR-T cell persistence during patient follow-up” – Di Yu, Co-founder of Elicera & Head of Translational Research & Technical Operations
Click here to read the full paper.
